Shulin Lu
Beth Israel Deaconess Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shulin Lu.
Blood | 2013
Guoqi Zhang; Li Yang; Gab Seok Kim; Kieran Ryan; Shulin Lu; Rebekah K. O'Donnell; Katherine Spokes; Nathan I. Shapiro; William C. Aird; Michael J. Kluk; Kiichiro Yano; Teresa Sanchez
The endothelium, as the interface between blood and all tissues, plays a critical role in inflammation. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid, highly abundant in plasma, that potently regulates endothelial responses through interaction with its receptors (S1PRs). Here, we studied the role of S1PR2 in the regulation of the proadhesion and proinflammatory phenotype of the endothelium. By using genetic approaches and a S1PR2-specific antagonist (JTE013), we found that S1PR2 plays a key role in the permeability and inflammatory responses of the vascular endothelium during endotoxemia. Experiments with bone marrow chimeras (S1pr2(+/+) → S1pr2(+/+), S1pr2(+/+) → S1pr2(-/-), and S1pr2(-/-) → S1pr2(+/+)) indicate the critical role of S1PR2 in the stromal compartment, in the regulation of vascular permeability and vascular inflammation. In vitro, JTE013 potently inhibited tumor necrosis factor α-induced endothelial inflammation. Finally, we provide detailed mechanisms on the downstream signaling of S1PR2 in vascular inflammation that include the activation of the stress-activated protein kinase pathway that, together with the Rho-kinase nuclear factor kappa B pathway (NF-kB), are required for S1PR2-mediated endothelial inflammatory responses. Taken together, our data indicate that S1PR2 is a key regulator of the proinflammatory phenotype of the endothelium and identify S1PR2 as a novel therapeutic target for vascular disorders.
Journal of Immunology | 2010
Nathan I. Shapiro; Eliyahu V. Khankin; Matijs Van Meurs; Shou-Ching Shih; Shulin Lu; Midori Yano; Pedro Castro; Eleftheria Maratos-Flier; Samir M. Parikh; S. Ananth Karumanchi; Kiichiro Yano
The adipose-derived hormone leptin is well known for its contribution to energy metabolism and satiety signaling in the hypothalamus. Previous studies suggested that obesity is an independent risk factor for sepsis morbidity and mortality, and it is associated with elevated baseline levels of circulating leptin in normal, nonseptic patients. In mouse endotoxemia and cecal ligation puncture models of sepsis, we observed elevated levels of leptin and soluble leptin receptor (sLR). Exogenously administered leptin increased mortality in endotoxemia and cecal ligation puncture models and was associated with increased expression of adhesion and coagulation molecules, macrophage infiltration into the liver and kidney, and endothelial barrier dysfunction. Conversely, longform leptin receptor-deficient mice were protected from sepsis morbidity and mortality and had less endothelial dysfunction. Furthermore, an in vitro study revealed that leptin-induced endothelial dysfunction is likely mediated, at least in part, by monocytes. Moreover, administration of an sLR conferred a survival benefit. Human septic patients have increased circulating sLR concentrations, which were correlated with disease severity indices. Together, these data support a pathogenic role for leptin signaling during sepsis.
Proceedings of the National Academy of Sciences of the United States of America | 2016
Chandra C. Ghosh; Sascha David; Ruyang Zhang; Anthony V. Berghelli; Katelyn Milam; Sarah J. Higgins; Jon T. Hunter; Aditi Mukherjee; Yongyue Wei; Mei Tran; Freeman Suber; Lester Kobzik; Kevin C. Kain; Shulin Lu; Ansgar Santel; Kiichiro Yano; Prajna P. Guha; Daniel J. Dumont; David C. Christiani; Samir M. Parikh
Significance Major infections, such as influenza and bacterial sepsis, kill millions of individuals yearly, most commonly from complications affecting the vasculature, such as acute respiratory distress syndrome. Poor outcomes from rare infections, such as Ebola virus disease, have also been linked to the vasculature. The basis for prominent vascular involvement in infectious syndromes remains poorly understood. The present work shows that humans exhibit common, yet highly consequential, genetic variation in the ability to sustain expression of a key homeostatic vascular receptor called tunica interna endothelial cell kinase 2. The results suggest that host determinants of the molecular vascular response to infection may have a heretofore underappreciated impact on clinical outcomes. They also suggest new means to identify at-risk individuals and personalize future therapies. Ligands of the endothelial-enriched tunica interna endothelial cell kinase 2 (Tie2) are markedly imbalanced in severe infections associated with vascular leakage, yet regulation of the receptor itself has been understudied in this context. Here, we show that TIE2 gene expression may constitute a novel vascular barrier control mechanism in diverse infections. Tie2 expression declined rapidly in wide-ranging models of leak-associated infections, including anthrax, influenza, malaria, and sepsis. Forced Tie2 suppression sufficed to attenuate barrier function and sensitize endothelium to permeability mediators. Rapid reduction of pulmonary Tie2 in otherwise healthy animals attenuated downstream kinase signaling to the barrier effector vascular endothelial (VE)-cadherin and induced vascular leakage. Compared with wild-type littermates, mice possessing one allele of Tie2 suffered more severe vascular leakage and higher mortality in two different sepsis models. Common genetic variants that influence TIE2 expression were then sought in the HapMap3 cohort. Remarkably, each of the three strongest predicted cis-acting SNPs in HapMap3 was also associated with the risk of acute respiratory distress syndrome (ARDS) in an intensive care unit cohort of 1,614 subjects. The haplotype associated with the highest TIE2 expression conferred a 28% reduction in the risk of ARDS independent of other major clinical variables, including disease severity. In contrast, the most common haplotype was associated with both the lowest TIE2 expression and 31% higher ARDS risk. Together, the results implicate common genetic variation at the TIE2 locus as a determinant of vascular leak-related clinical outcomes from common infections, suggesting new tools to identify individuals at unusual risk for deleterious complications of infection.
Shock | 2012
Matijs van Meurs; Pedro Castro; Nathan I. Shapiro; Shulin Lu; Midori Yano; Norikazu Maeda; Tohru Funahashi; Ichiro Shimomura; Jan G. Zijlstra; Grietje Molema; Samir M. Parikh; William C. Aird; Kiichiro Yano
Experimental sepsis was induced in male C57BL/6j, adiponectin-deficient mice (ADPNKO), and wild-type littermates by i.p. injection of 16 mg/kg lipopolysaccharide or cecal ligation and puncture. Blood and tissue samples were harvested 24 h after model induction. Circulating adiponectin is reduced in mice with endotoxemic challenge and after cecal ligation and puncture compared with healthy control mice. Quantitative reverse transcriptase–polymerase chain reaction for adiponectin reveals a pattern of response that is both model- and organ-specific. When challenged with sepsis, adiponectin deficiency results in increased expression of endothelial adhesion and coagulation molecules in the lung, liver, and kidney as quantified by reverse transcriptase–polymerase chain reaction, increased macrophage and neutrophil infiltration by immunohistochemistry, and vascular leakage in the liver and kidney. Adiponectin-deficient mice have reduced survival following cecal ligation and puncture and increased blood levels of interleukin 6, soluble vascular endothelial growth factor receptor 1, and soluble endothelial adhesion molecules E-selectin and intercellular adhesion molecule 1. Finally, ADPNKO promoted end-organ injury in the liver and kidney, whereas the lungs were not affected. These data suggest a protective role of adiponectin in diminishing microvascular organ-specific endothelial cell activation during sepsis. ABBREVIATIONS LPS—lipopolysaccharide CLP—cecal ligation and puncture sVEGFR1—soluble vascular endothelial growth factor receptor 1 IL-6 – interleukin 6 ICAM-1—intercellular adhesion molecule 1 VCAM-1—vascular cell adhesion molecule 1
Journal of Clinical Investigation | 2018
Sarah J. Higgins; Karen De Ceunynck; John A. Kellum; Xiuying Chen; Xuesong Gu; Sharjeel A. Chaudhry; Sol Schulman; Towia A. Libermann; Shulin Lu; Nathan I. Shapiro; David C. Christiani; Robert Flaumenhaft; Samir M. Parikh
Disordered coagulation contributes to death in sepsis and lacks effective treatments. Existing markers of disseminated intravascular coagulation (DIC) reflect its sequelae rather than its causes, delaying diagnosis and treatment. Here we show that disruption of the endothelial Tie2 axis is a sentinel event in septic DIC. Proteomics in septic DIC patients revealed a network involving inflammation and coagulation with the Tie2 antagonist, angiopoietin-2 (Angpt-2), occupying a central node. Angpt-2 was strongly associated with traditional DIC markers including platelet counts, yet more accurately predicted mortality in 2 large independent cohorts (combined N = 1,077). In endotoxemic mice, reduced Tie2 signaling preceded signs of overt DIC. During this early phase, intravital imaging of microvascular injury revealed excessive fibrin accumulation, a pattern remarkably mimicked by Tie2 deficiency even without inflammation. Conversely, Tie2 activation normalized prothrombotic responses by inhibiting endothelial tissue factor and phosphatidylserine exposure. Critically, Tie2 activation had no adverse effects on bleeding. These results mechanistically implicate Tie2 signaling as a central regulator of microvascular thrombus formation in septic DIC and indicate that circulating markers of the Tie2 axis could facilitate earlier diagnosis. Finally, interventions targeting Tie2 may normalize coagulation in inflammatory states while averting the bleeding risks of current DIC therapies.
Lab on a Chip | 2016
Edward J. Felton; Anthony Velasquez; Shulin Lu; Ryann O. Murphy; Abdala ElKhal; Ofer Mazor; Pavel Gorelik; Anish Sharda; Ionita Ghiran
Nature Biotechnology | 2018
Maria D. Giraldez; Ryan M Spengler; Alton Etheridge; Pm Godoy; Andrea J. Barczak; Srimeenakshi Srinivasan; Peter L De Hoff; Amanda Courtright; Shulin Lu; Joseph A. Khoory; Renee Rubio; David Baxter; Tom A. P. Driedonks; Henk P. J. Buermans; Esther N.M. Nolte-'t Hoen; Hui Jiang; Kai Wang; Ionita Ghiran; Yaoyu E. Wang; Kendall Van Keuren-Jensen; Jane E. Freedman; Prescott G. Woodruff; Louise C. Laurent; David J. Erle; David J. Galas; Muneesh Tewari
Protocol exchange | 2018
Giraldez; Rm Spengler; Alton Etheridge; Pm Godoy; Andrea J. Barczak; Srimeenakshi Srinivasan; Pl De Hoff; Amanda Courtright; Shulin Lu; Joseph A. Khoory; Renee Rubio; David Baxter; Tap Driedonks; Hpj Buermans; Enm Nolte-t Hoen; Hui Jiang; Kai Wang; Ionita Ghiran; Yaoyu E. Wang; K Van Keuren-Jensen; Jane E. Freedman; Prescott G. Woodruff; Louise C. Laurent; David J. Erle; David J. Galas; Muneesh Tewari
Shock | 2018
Mikkel Schou Andersen; Shulin Lu; Gregory J. Lopez; Annmarie Touborg Lassen; Nathan I. Shapiro; Ionita Ghiran
Protocol exchange | 2018
Giraldez; Rm Spengler; Alton Etheridge; Pm Godoy; Andrea J. Barczak; Srimeenakshi Srinivasan; Pl De Hoff; Amanda Courtright; Shulin Lu; Joseph A. Khoory; Renee Rubio; David Baxter; Tap Driedonks; Hpj Buermans; Enm Nolte-t Hoen; Hui Jiang; Kai Wang; Ionita Ghiran; Yaoyu E. Wang; K Van Keuren-Jensen; Jane E. Freedman; Prescott G. Woodruff; Louise C. Laurent; David J. Erle; David J. Galas; Muneesh Tewari